Cuffless blood pressure measurement in a wristwatch is one of the most requested features in consumer health technology — and one of the most technically challenging to deliver with clinical accuracy. Hypertension affects nearly 1.3 billion people globally, is a leading modifiable risk factor for heart attack and stroke, and is dramatically undertreated in part because blood pressure measurement requires equipment most people don't carry. The appeal of a watch that checks blood pressure continuously is enormous. The gap between that appeal and current technical reality is equally significant.
How Cuffless Blood Pressure Measurement Works
Traditional sphygmomanometry — the cuff-based method — works by inflating a bladder around the upper arm to occlude the brachial artery, then slowly releasing pressure while detecting the return of blood flow sounds (Korotkoff sounds) or oscillometric pressure waves. It directly measures the hydrostatic pressure required to occlude and allow flow through a major artery.
Cuffless devices use indirect methods that estimate blood pressure from relationships between measurable signals and underlying pressure dynamics:
Pulse Transit Time (PTT): The most common approach, used by Samsung Galaxy Watch and most other cuffless wearables. PTT measures the time delay between the electrical R-wave of the heartbeat (detected by ECG electrodes) and the arrival of the pulse wave at the wrist (detected by PPG optical sensors). Arterial blood pressure relates to pulse wave velocity — higher pressure stiffens arteries, which conducts pulse waves faster, shortening PTT. The problem: the relationship between PTT and pressure requires calibration against a reference measurement, changes with hydration status, arterial stiffness, temperature, and vascular tone, and varies substantially between individuals.
PPG Morphology Analysis: A newer approach examining the shape of the photoplethysmography waveform — the rise time, diastolic notch depth, and decay characteristics — to infer vascular tone and pressure. AI/ML models trained on large datasets can extract blood pressure estimates from PPG waveforms without requiring an ECG electrode. Accuracy in validation studies has been marginal — typically worse than PTT methods — though active research is improving this.
Oscillometric Wrist Cuffs: True wrist cuffs that inflate and deflate, measuring oscillometric pressure waves at the wrist. More accurate than PTT but significantly less convenient and historically problematic for consistent positioning — the wrist must be held at heart level during measurement, which is difficult to achieve consistently.
Validation Standards: What They Mean
Two major validation protocols exist for blood pressure measuring devices:
IEEE 1708 Standard (2012): Designed specifically for wearable cuffless devices, with a more lenient accuracy requirement: mean difference ≤5 mmHg and standard deviation ≤8 mmHg in validation testing. This standard has been criticized for setting an accuracy bar too low for clinical utility.
ESH 2020 Protocol: The European Society of Hypertension's standard, requiring mean differences ≤5 mmHg and SD ≤8 mmHg, with additional testing requirements including validation across a range of blood pressures including hypertensive ranges, and a minimum number of validation subjects. Obtaining ESH 2020 certification is more rigorous than IEEE 1708.
It's important to understand what validation certification means: a device passing these standards meets a minimum accuracy threshold in controlled validation conditions. Real-world accuracy — across all positions, activity levels, skin tones, and hydration states — is typically worse than validation study performance.
Samsung Galaxy Watch 6 and 7: The Most Validated Option
Samsung has invested more in blood pressure validation research than any other smartwatch manufacturer. The Galaxy Watch 5, 6, and 7 all use PTT-based blood pressure estimation via the Samsung Health Monitor app, which has received CE marking for blood pressure monitoring in Europe and regulatory approval in South Korea and some other markets.
The Samsung implementation requires calibration: before each blood pressure measurement session, the user must take two reference readings with a validated upper-arm cuff and enter them into the app. The app uses these values to calibrate the PTT-to-pressure conversion for that session. Without calibration, no mmHg values are displayed.
Even with calibration, Samsung's published validation data shows mean absolute errors of approximately 6–8 mmHg for systolic pressure and 4–6 mmHg for diastolic — acceptable for population-level screening research but insufficient for individual clinical decisions. A ±8 mmHg error means a reading of 138 mmHg could represent true blood pressure anywhere from 130–146 mmHg, spanning the critical clinical threshold of 140 mmHg (Stage 1 hypertension).
Apple Watch Blood Pressure Feature: Current Status
Apple Watch Series 10 contains the necessary hardware for cuffless blood pressure estimation. The feature has launched in limited markets in Europe and Asia with CE authorization, but has not received FDA authorization for US deployment as of late 2026. Apple's implementation appears to use a combined PPG + electrical heart sensor approach, leveraging both optical and electrical signals to improve PTT estimation accuracy.
Independent accuracy data from early adopters in authorized markets suggests performance comparable to Samsung Galaxy Watch — useful for trend detection, not sufficient for clinical thresholds. Apple's conservative approach to medical feature rollout, demonstrated by the multi-year gap between ECG hardware availability and FDA clearance, suggests the company is accumulating validation data before broader deployment.
FDA Clearance vs Clinical Validation: An Important Distinction
FDA clearance (510(k) pathway) means a device has been shown to be substantially equivalent to a legally marketed predicate device. It does not require demonstration of clinical effectiveness or superiority to existing treatments. For blood pressure devices, FDA clearance via the 510(k) pathway requires accuracy data meeting specific thresholds, but the thresholds have evolved and legacy devices can use older, less rigorous standards as predicates.
When evaluating a blood pressure wearable's accuracy claims, look for:
- Peer-reviewed published validation studies (not just manufacturer white papers)
- ESH 2020 certification (more rigorous than FDA clearance alone)
- Validation sample size (minimum 85 subjects per ESH 2020)
- Validation across hypertensive range (BP ≥ 140/90), not just normotensive subjects
- Independent validation (not funded solely by the manufacturer)
This distinction has concrete consequences for consumers. FDA clearance via the 510(k) pathway establishes safety — the device won't harm you — and basic efficacy in the sense of performing better than chance. What it does not establish is whether the device is accurate enough to guide clinical decisions, because the FDA clearance threshold and the clinical utility threshold are not the same standard. The European Society of Hypertension International Protocol (ESH-IP 2020) and the British and Irish Hypertension Society (BIHS) grading system provide the most rigorous validation framework, requiring testing across hypertensive ranges, minimum subject counts, and independent replication. Consumers evaluating cuffless BP wearables should specifically look for devices validated to ESH-IP 2020 criteria rather than simply FDA-cleared — these are meaningfully different bars. As of 2026, only a handful of cuffless BP wearables have published ESH-IP 2020 validation data in the peer-reviewed literature; the majority of marketed devices rely on FDA clearance alone, which tells you considerably less about real-world clinical accuracy.
Ambulatory Blood Pressure Monitoring: The Gold Standard
The clinical gold standard for blood pressure assessment is ambulatory blood pressure monitoring (ABPM) — wearing a traditional inflating upper-arm cuff that takes readings every 15–30 minutes over 24 hours. ABPM is superior to office measurements and to home cuff readings because it captures blood pressure variability across sleep, work, and activity, identifies white coat hypertension (office readings elevated, ambulatory normal) and masked hypertension (office readings normal, ambulatory elevated), and provides a comprehensive picture that single readings cannot.
ABPM is prescribed by cardiologists and requires wearing a cumbersome device for a full day and night. The appeal of a smartwatch that provides continuous BP monitoring is precisely that it could deliver ABPM-quality data in a more convenient form. Current cuffless wearables aren't there yet, but the technological trajectory is moving toward that goal.
Practical Recommendations for 2026
The most clinically useful blood pressure monitoring approach available in 2026 remains a validated upper-arm cuff (Omron EVOLV, Withings BPM Connect, or similar) used regularly at home, with readings stored in your health app for trend analysis. Bluetooth-enabled cuffs sync readings automatically and build the longitudinal dataset useful for clinical consultations.
For people who want wearable blood pressure monitoring, Samsung Galaxy Watch 6 or 7 with the Health Monitor app provides the most validated cuffless option. Treat readings as trend data: if the watch consistently shows elevated readings, confirm with a cuff; if readings are consistently normal over weeks, that provides some reassurance. Never use wearable blood pressure readings as the sole basis for medication decisions.
The next 2–3 years are likely to see meaningful improvements in cuffless accuracy as AI-driven PPG morphology analysis matures and Apple enters the US market with FDA authorization. Until then, the gap between wearable convenience and clinical-grade accuracy remains real and clinically relevant.